TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
About Us About Us

COMPANY PROFILE

Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628. 


Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. 


Our Team

Leadership Leadership
Directors Directors
Advisors Advisors

MILESTONES

Aug 2010
Incorporated Mabspace International Limited in the BVI
Oct 2012
Established Mabspace Biosciences (Suzhou)
Jun 2013
Developed the Immune Tolerance Breaking Technology Platform (IMTB)
Feb 2016
Established HJB (Hangzhou) Co., Ltd.
Mar 2017
Built T-BLOC facility with G-CON in Hangzhou
Feb 2018
Obtained MSB2311 IND clearance from FDA
Apr 2018
MSB2311 initiated Phase I clinical trial in US
May 2018
Obtained MSB2311 IND clearance from NMPA
Jan 2019
Mabspace & HJB merged to establish Transcenta
Mar 2019
In-licensed Blosozumab (TST002)
Sept 2019
Obtained MSB0254 IND clearance from NMPA
Apr 2020
Obtained TST001 IND clearance from NMPA and FDA
Jul 2020
First patient dosed in phase I clinical trial of TST001 in US
Nov 2020
Formed collaboration with Merck to co-develop continuous downstreaming manufacturing technology
Nov 2020
Formed JV with Alebund for co-development of TST004 for renal disease in China
Apr 2021
Obtained TST005 IND clearance from FDA;
First patient dosed in Phase I clinical trial of TST001 combined with CAPOX
May 2021
MSB2311 clinical efficacy and safety reported at ASCO 2021
Jul 2021
Partial responses observed in the TST001 monotherapy dose-escalation trial;
First patient dosed in global Phase I clinical trial of TST005 in US
Aug 2021
Held investigator meeting and first patient dosed in Phase IIa clinical trial of TST001 in China
Sept 2021
HKEX Listing (Stock Code: 6628);
Obtained TST002 IND clearance from NMPA
Nov 2021
First patient dosed in Phase Ib clinical trial of MSB0254

Albert Zhu CPA

SVP Finance Business Operations

Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.